Physician profile
Tiffany Ferrante
NPI 1437750783
$2,533.63
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,563 · 2022: $733 · 2023: $224 · 2024: $14.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $595.06 | 2021-2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $336.85 | 2021-2022 | |
| Esperion Therapeutics, INC. | $325.09 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.51 | 2021-2022 | |
| Amarin Pharma, INC. | $230.32 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $181.58 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $117.22 | 2021-2022 | |
| Glaxosmithkline, LLC. | $98.98 | 2023 | Trelegy Ellipta |
| Abbvie INC. | $93.72 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $87.93 | 2021 | |
| Lilly USA, LLC | $61.99 | 2021-2022 | |
| Philips North America LLC | $41.13 | 2021 | |
| Allergan, INC. | $29.55 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.74 | 2022 | |
| Amgen INC. | $16.49 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $14.20 | 2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Ferrante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.